On Wednesday, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), lost -3.83% to $2.01, hitting its lowest level.
Advanced Micro Devices, declared its new AMD Catalyst™ 15.7 Driver update delivering seamless and intuitive support for Windows® 10 and the DirectX® 12 API, and is a primary ingredient for users to get the most out of their AMD APU and GPU solutions.
The AMD Catalyst 15.7 driver is a foundational driver that will assist enrich the user experience through more reliable performance, innovative features and technologies. The AMD Catalyst™ driver will be fully integrated with Microsoft® Windows 10 as part of the Windows driver update component.
AMD APUs and Radeon™ GPUs running Windows® 10 will be able to deliver a highly advanced entertainment experience by making games and streaming video look better than ever; making the PC experience more personal, more productive and seamless across devices.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of DepoMed Inc. (NASDAQ:DEPO), declined -0.49% to $28.48, during its last trading session, hitting its highest level.
Depomed, declared the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office issued its final decision in the inter partes review proceedings (IPRs) initiated by Purdue Pharma against two Depomed patents (U.S. Patent Nos. 6,340,475 and 6,635,280). The PTAB has confirmed the patentability of each of the 25 claims subject to the IPRs.
“We will now continue our patent infringement case against Purdue,” said Jim Schoeneck, president and chief executive officer of Depomed. “We are happy the PTAB acknowledged the innovation of these patents, which have been successfully asserted in litigation nearly a dozen times since 2002 and have been licensed to our industry peers in about 20 transactions.”
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
Finally, Angie’s List, Inc. (NASDAQ:ANGI), ended its last trade with -0.97% loss, and closed at $6.10.
Angie’s List, declared that its second quarter 2015 financial results will be released on Wednesday, July 22, 2015, before the open of the market. The company will host a conference call at 8:30 a.m. ET to talk about the financial results with the investment community.
Angie’s List, Inc. operates a local services marketplace and consumer review site in the United States. The company provides marketplace to research, shop for, and purchase local services for home, health, and automotive service needs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
